Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Heinemann, V; Niedzwiecki, D; Pearline, RV; Grothey, A; Hochster, HS; Goldberg, RM; Innocenti, F; Mayer, RJ; Schilsky, RL; Blanke, CD; Bertagnolli, MM; Venook, AP; Stinzing, S; O'Neil, BH

Published Date

  • May 20, 2015

Published In

Volume / Issue

  • 33 / 15_suppl

Start / End Page

  • 3585 - 3585

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2015.33.15_suppl.3585